Jundishapur Journal of Microbiology

Published by: Kowsar

In Vitro Susceptibility and Trailing Growth Effect of Clinical Isolates of Candida Species to Azole Drugs

Kamiar Zomorodian 1 , 2 , Azadeh Bandegani 3 , Hossein Mirhendi 2 , Keyvan Pakshir 1 , 2 , Navvab Alinejhad 3 and Ali Poostforoush Fard 1 , *
Authors Information
1 Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Department of Medical Mycology and Parasitology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Jundishapur Journal of Microbiology: February 01, 2016, 9 (2); e28666
  • Published Online: February 20, 2016
  • Article Type: Research Article
  • Received: April 7, 2015
  • Revised: October 10, 2015
  • Accepted: November 30, 2015
  • DOI: 10.5812/jjm.28666

To Cite: Zomorodian K, Bandegani A, Mirhendi H, Pakshir K, Alinejhad N, et al. In Vitro Susceptibility and Trailing Growth Effect of Clinical Isolates of Candida Species to Azole Drugs, Jundishapur J Microbiol. 2016 ; 9(2):e28666. doi: 10.5812/jjm.28666.

Abstract
Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Zomorodian K, Haghighi NN, Rajaee N, Pakshir K, Tarazooie B, Vojdani M, et al. Assessment of Candida species colonization and denture-related stomatitis in complete denture wearers. Med Mycol. 2011; 49(2): 208-11[DOI][PubMed]
  • 2. Wanke B, Lazera Mdos S, Nucci M. Fungal infections in the immunocompromised host. Mem Inst Oswaldo Cruz. 2000; 95 Suppl 1: 153-8[PubMed]
  • 3. Schelenz S, Abdallah S, Gray G, Stubbings H, Gow I, Baker P, et al. Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors. J Oral Pathol Med. 2011; 40(1): 83-9[DOI][PubMed]
  • 4. Alangaden GJ. Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin North Am. 2011; 25(1): 201-25[DOI][PubMed]
  • 5. Brissaud O, Guichoux J, Harambat J, Tandonnet O, Zaoutis T. Invasive fungal disease in PICU: epidemiology and risk factors. Ann Intensive Care. 2012; 2(1): 6[DOI][PubMed]
  • 6. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care. 2010; 16(5): 445-52[DOI][PubMed]
  • 7. Tan TY, Tan AL, Tee NW, Ng LS, Chee CW. The increased role of non-albicans species in candidaemia: results from a 3-year surveillance study. Mycoses. 2010; 53(6): 515-21[DOI][PubMed]
  • 8. Farooqi JQ, Jabeen K, Saeed N, Iqbal N, Malik B, Lockhart SR, et al. Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility. J Med Microbiol. 2013; 62: 259-68[DOI][PubMed]
  • 9. Oberoi JK, Wattal C, Goel N, Raveendran R, Datta S, Prasad K. Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India. Indian J Med Res. 2012; 136(6): 997-1003[PubMed]
  • 10. Ma CF, Li FQ, Shi LN, Hu YA, Wang Y, Huang M, et al. Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China. BMC Infect Dis. 2013; 13: 337[DOI][PubMed]
  • 11. Montravers P, Jabbour K. Clinical consequences of resistant Candida infections in intensive care. Int J Antimicrob Agents. 2006; 27(1): 1-6[DOI][PubMed]
  • 12. Arendrup MC, Fuursted K, Gahrn-Hansen B, Schonheyder HC, Knudsen JD, Jensen IM, et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect. 2008; 14(5): 487-94[DOI][PubMed]
  • 13. Kam LW, Lin JD. Management of systemic candidal infections in the intensive care unit. Am J Health Syst Pharm. 2002; 59(1): 33-41[PubMed]
  • 14. Wayne P. Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-; CLSI document M27-A3. CLSI 2008a. 2008; 28: 6-12
  • 15. European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility T. EUCAST technical note on fluconazole. Clin Microbiol Infect. 2008; 14(2): 193-5[DOI][PubMed]
  • 16. Subcommittee on Antifungal Susceptibility Testing of the EECFAST. EUCAST Technical Note on voriconazole. Clin Microbiol Infect. 2008; 14(10): 985-7[DOI][PubMed]
  • 17. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones RN. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol. 2010; 48(5): 1592-9[DOI][PubMed]
  • 18. Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012; 50(9): 2846-56[DOI][PubMed]
  • 19. Coenye T, De Vos M, Vandenbosch D, Nelis H. Factors influencing the trailing endpoint observed in Candida albicans susceptibility testing using the CLSI procedure. Clin Microbiol Infect. 2008; 14(5): 495-7[DOI][PubMed]
  • 20. Lee MK, Williams LE, Warnock DW, Arthington-Skaggs BA. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother. 2004; 53(2): 217-24[DOI][PubMed]
  • 21. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, Rodriguez-Tudela JL. Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol. 2001; 39(2): 525-32[DOI][PubMed]
  • 22. Agrawal D, Patterson TF, Rinaldi MG, Revankar SG. Trailing end-point phenotype of Candida spp. in antifungal susceptibility testing to fluconazole is eliminated by altering incubation temperature. J Med Microbiol. 2007; 56: 1003-4[DOI][PubMed]
  • 23. Braga-Silva LA, Mesquita DG, Ribeiro MD, Carvalho SM, Fracalanzza SE, Santos AL. Trailing end-point phenotype antibiotic-sensitive strains of Candida albicans produce different amounts of aspartyl peptidases. Braz J Med Biol Res. 2009; 42(8): 765-70[PubMed]
  • 24. Rodriguez-Tudela JL, Martinez-Suarez JV. Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrob Agents Chemother. 1994; 38(1): 45-8[PubMed]
  • 25. Marr KA, Rustad TR, Rex JH, White TC. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother. 1999; 43(6): 1383-6[PubMed]
  • 26. Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie EJ. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother. 1998; 42(1): 129-34[PubMed]
  • 27. Revankar SG, Kirkpatrick WR, McAtee RK, Fothergill AW, Redding SW, Rinaldi MG, et al. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol. 1998; 36(1): 153-6[PubMed]
  • 28. Mirhendi H, Makimura K, Khoramizadeh M, Yamaguchi H. A One-Enzyme PCR-RFLP Assay for Identification of Six Medically Important Candida Species. Nippon Ishinkin Gakkai Zasshi. 2006; 47(3): 225-9[DOI]
  • 29. Mirhendi H, Makimura K, Zomorodian K, Maeda N, Ohshima T, Yamaguchi H. Differentiation of Candida albicans and Candida dubliniensis using a single-enzyme PCR-RFLP method. Jpn J Infect Dis. 2005; 58(4): 235-7[PubMed]
  • 30. Yamada Y, Makimura K, Merhendi H, Ueda K, Nishiyama Y, Yamaguchi H, et al. Comparison of different methods for extraction of mitochondrial DNA from human pathogenic yeasts. Jpn J Infect Dis. 2002; 55(4): 122-5[PubMed]
  • 31. Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med. 2010; 13(4): 282-7[PubMed]
  • 32. Panizo MM, Reviakina V, Dolande M, Selgrad S. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol. 2009; 47(2): 137-43[DOI][PubMed]
  • 33. Lee JS, Shin JH, Lee K, Kim MN, Shin BM, Uh Y, et al. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J. 2007; 48(5): 779-86[DOI][PubMed]
  • 34. Silva V, Alvarado D, Diaz MC. Antifungal susceptibility of 50 Candida isolates from invasive mycoses in Chile. Med Mycol. 2004; 42(3): 283-5[PubMed]
  • 35. Citak S, Ozcelik B, Cesur S, Abbasoglu U. In vitro susceptibility of Candida species isolated from blood culture to some antifungal agents. Jpn J Infect Dis. 2005; 58(1): 44-6[PubMed]
  • 36. Shokohi T, Bandalizadeh Z, Hedayati MT, Mayahi S. In vitro antifungal susceptibility of Candida species isolated from oropharyngeal lesions of patients with cancer to some antifungal agents. Jundishapur J Microbiol. 2011; 4(2)-26
  • 37. Fleck R, Dietz A, Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother. 2007; 59(4): 767-71[DOI][PubMed]
  • 38. Kotwal A, Biswas D, Sharma JP, Gupta A, Jindal P. An observational study on the epidemiological and mycological profile of Candidemia in ICU patients. Med Sci Monit. 2011; 17(11)-8[PubMed]
  • 39. Mulu A, Kassu A, Anagaw B, Moges B, Gelaw A, Alemayehu M, et al. Frequent detection of 'azole' resistant Candida species among late presenting AIDS patients in northwest Ethiopia. BMC Infect Dis. 2013; 13: 82[DOI][PubMed]
  • 40. Zarei Mahmoudabadi A, Zarrin M, Beheshti Fard M. Antifungal susceptibility of Candida species isolated from candidura. Jundishapur J Microbiology. 2012; 6(1): 24-8[DOI]
  • 41. Salehei Z, Seifi Z, Mahmoudabadi A. Sensitivity of Vaginal Isolates of Candida to Eight Antifungal Drugs Isolated From Ahvaz, Iran. Jundishapur J Microbiology. 2012; 5(4): 574-7[DOI]
  • 42. Parisa B, Alborzi A, Shakiba E, Ziyaeyan M, Rasuli M. Molecular Identification and In-Vitro Susceptibility of Candida albicans and C. dubliniensis Isolated from Immu-nocompromised Patients. IRCMJ. 2009; 2009(4): 391-7
  • 43. Khosravi AR, Shokri H, Mansouri P, Katiraee F, Ziglari T. Candida species isolated from nails and their in vitro susceptibility to antifungal drugs in the department of Dermatology (University of Tehran, Iran). Med J Mycol. 2008; 18(4): 210-5[DOI]
  • 44. Seman MS, Ramli RB, khaithir TMN. Antifungal susceptibility patterns among Candida species isolated from blood at Universiti Kebangsaan Malaysia Medical Centre. Sains Malaysiana. 2012; 41(8): 961-7
  • 45. Metin DY, Hilmioglu-Polat S, Samlioglu P, Doganay-Oflazoglu B, Inci R, Tumbay E. Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates. Mycopathologia. 2011; 172(3): 187-99[DOI][PubMed]
  • 46. Badiee P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran J Microbiol. 2011; 3(4): 183-8[PubMed]
  • 47. Peman J, Canton E, Quindos G, Eraso E, Alcoba J, Guinea J, et al. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother. 2012; 67(5): 1181-7[DOI][PubMed]
  • 48. Taura DW, Maje MH, Koki AM, Musa MG. Antifungal Resistance Among Candida species From Patients with Genitourinary Tract Infection at Muhammad Abdullahi Wase Specialist Hospital, Kano - Nigeria. Nigerian J Basic Appl Sci. 2013; 21(1)[DOI]
  • 49. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003; 47(10): 3149-54[PubMed]
  • 50. Girmenia C, Tuccinardi C, Santilli S, Mondello F, Monaco M, Cassone A, et al. In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies. J Antimicrob Chemother. 2000; 46(3): 479-83[PubMed]
  • 51. Arthington-Skaggs BA, Lee-Yang W, Ciblak MA, Frade JP, Brandt ME, Hajjeh RA, et al. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother. 2002; 46(8): 2477-81[PubMed]
  • 52. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007; 51(1): 35-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments